NICOLE GUILLORY: Open Payments
NPI 1598244006 · ALEXANDRIA, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,143 in 53 payments from 12 companies in 2025. Trend: 2023 $383 · 2024 $826 · 2025 $1,143
Food & beverage: $1,128Education: $15
| Company | Payments | Amount |
|---|---|---|
| Fresenius USA Marketing, Inc. | 15 | $277 |
| AstraZeneca Pharmaceuticals LP | 10 | $194 |
| Calliditas Therapeutics US Inc. | 6 | $158 |
| Novo Nordisk Inc | 5 | $113 |
| Novartis Pharmaceuticals Corporation | 4 | $98 |
| Otsuka America Pharmaceutical, Inc. | 3 | $94 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $79 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $40 |
| SCPHARMACEUTICALS INC. | 2 | $36 |
| Travere Therapeutics, Inc. | 1 | $25 |
Products named: VELPHORO, LOKELMA, TARPEYO, Kerendia, Fabhalta, JYNARQUE, Rybelsus, Wegovy.
Industry payments across LA — which companies pay providers there.
